More Telix Pharmaceuticals Limited news
Telix Pharmaceuticals LimitedASX: TLX

S&P DJI Announces June 2020 Quarterly Rebalance

Jun 11, 2020 at 10:36 PM EDT · Issued by Telix Pharmaceuticals Limited

Filed with ASX · Jun 11, 2020 at 10:36 PM EDT · 10 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-june-2020-quarterly-rebalance-61

Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20↗

Telix Pharmaceuticals Limited on 6ix

Earlier from Telix Pharmaceuticals

  • Appendix 4C and Activity Report March 2020 quarterApr 20, 2020
  • Commercial Distribution Agmt for Prostate Cancer DiagnosticApr 8, 2020
  • Telix completes acquisition of licensed production facilityApr 2, 2020
  • Telix and partners receive 500k CRC research grantMar 15, 2020
  • Positive FDA feedback on NDA submission processFeb 24, 2020

Later from Telix Pharmaceuticals

  • FDA grants breakthrough designation for TLX250-CDx productJun 30, 2020
  • Receipt of $11.4M R&D tax rebateJul 21, 2020
  • Appendix 4C and Activities Report - June 2020 quarterJul 26, 2020
  • Report for half-year to 30 June 2020Aug 20, 2020
  • FDA grants orphan drug designation for TLX102Aug 30, 2020
All Telix Pharmaceuticals news releases↗

Follow Telix Pharmaceuticals into a list and get an email when it puts out news.

Follow Telix Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer